Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 167

Sort by

Sort Order Select

Journal Articles

Isatuximab for relapsed and/or refractory AL amyloidosis: results of a prospective phase 2 trial (SWOG S1702)

Terri L. Parker, Adam Rosenthal, Vaishali Sanchorawala, Heather J. Landau, Erica L. Campagnaro, Prashant Kapoor, Natalia Neparidze, Saulius Girnius, Patrick Hagen, Emma C. Scott, Antje Hoering, Brian G. M. Durie, Robert Z. Orlowski

Blood (2025) 146 (21): 2507–2516.

https://doi.org/10.1182/blood.2024027962

Published: 2025

Journal Articles

A phase I/II, open label, Study to evaluate safety, tolerability and efficacy of elranatamab in patients with relapsed or refractory AL amyloidosis: Interim report of phase I results

Shahrier Hossain, Adam Sperling, Jacob Laubach, Shannon Miller, Pedro Vianna, Emily Simpson, Madison Chuma, Brendan Fink, Samantha Geberth, Emily Magnavita, Jack Khouri, James Hoffman, Jonathan Kaufman, Vaishali Sanchorawala, Raymond Comenzo, Giada Bianchi

Blood (2025) 146 (Supplement 1): 5808.

https://doi.org/10.1182/blood-2025-5808

Published: 2025

Journal Articles

Effectiveness of second-line therapies following upfront daratumumab plus bortezomib, cyclophosphamide and dexamethasone: A new benchmark

Eugene Brailovski, Xia Wu, Grace Gallagher, Mithat Gonen, Andrew Staron, Abhishek Janardan, Vaishali Sanchorawala, Christopher Wanjiku, Sascha Tuchman, Amelia Piteo, Jeffrey Zonder, Alfred Chung, Victor Jimenez-Zepeda, Raymond Comenzo, Heather Landau

Blood (2025) 146 (Supplement 1): 5746.

https://doi.org/10.1182/blood-2025-5746

Published: 2025

Journal Articles

Cyclin D1 immunostaining as a diagnostic surrogate for the t(11;14) translocation in AL amyloidosis

Thomas George, Andrew Staron, Eric Burks, Raphael Szalat, Vaishali Sanchorawala

Blood (2025) 146 (Supplement 1): 5739.

https://doi.org/10.1182/blood-2025-5739

Published: 2025

Journal Articles

Single-cell transcriptomics of AL amyloidosis reveals pathogenic mechanisms, immune interactions and altered clonal and polyclonal plasma cell phenotypes

Jackson Smith, Mehmet Samur, Srikanth Talluri, Domenico Maisano, Michela Cumerlato, Charlotte Royer, Fatima Zohura, Sherry Wong, Gareth Morgan, Vaishali Sanchorawala, Nikhil Munshi, Raphael Szalat

Blood (2025) 146 (Supplement 1): 3923.

https://doi.org/10.1182/blood-2025-3923

Published: 2025

Journal Articles

An open-label multicenter Phase 1/2 trial of venetoclax-dexamethasone in Relapsed/Refractory t(11;14)-positive systemic AL amyloidosis

Rajshekhar Chakraborty, Anita D'Souza, Prashant Kapoor, Shikun Wang, Divaya Bhutani, Susan Bal, Keith Stockerl-Goldstein, Sherin Selvan, Othman Akhtar, Vaishali Sanchorawala, Suzanne Lentzsch

Blood (2025) 146 (Supplement 1): 694.

https://doi.org/10.1182/blood-2025-694

Published: 2025

Journal Articles

IgD-related AL amyloidosis: Clinical features and outcomes

Sarika Gurnani, Andrew Staron, John Mark Sloan, Lisa Mendelson, Tracy Joshi, Natasha Burke, Vaishali Sanchorawala

Blood (2025) 146 (Supplement 1): 7500.

https://doi.org/10.1182/blood-2025-7500

Published: 2025

Journal Articles

First 20-patient safety and efficacy data from nexicart-2, the first u.S. trial of CAR-T in R/R light chain (AL) amyloidosis, nxc-201

Heather Landau, Shahzad Raza, Aaron Rosenberg, Jeffrey Zonder, Raymond Comenzo, Vaishali Sanchorawala, Michaela Liedtke, Amandeep Godara, Michael Rosenzweig, Charlotte Hughes, Eugene Brailovski, Mehrdad Abedi, Sham Mailankody, Jae Park, David Marks, Sridevi Rajeeve, Jennifer Liu

Blood (2025) 146 (Supplement 1): 696.

https://doi.org/10.1182/blood-2025-696

Published: 2025

Journal Articles

Sustained measurable residual disease (MRD) in light chain amyloidosis: The added value of durability over depth alone

Andrew Staron, Eric Burks, Vaishali Sanchorawala

Blood (2025) 146 (Supplement 1): 695.

https://doi.org/10.1182/blood-2025-695

Published: 2025

Journal Articles

Phase 1/2 dose escalation and expansion study of etentamig in patients with relapsed or refractory light chain amyloidosis

Blood (2025) 146 (Supplement 1): 692.

https://doi.org/10.1182/blood-2025-692

Published: 2025

Journal Articles

Impact-AL: A phase 2 clinical trial of teclistamab and daratumumab in previously untreated AL amyloidosis

Rajshekhar Chakraborty, Anita D'Souza, Omar Siddiqi, Shikun Wang, Margaret Doyle, Sanjay Vara, Benjamin Schroeder, Jordan Schecter, Catherine Higgins, Renee Smith, Vaishali Sanchorawala, Suzanne Lentzsch

Blood (2025) 146 (Supplement 1): 2197.

https://doi.org/10.1182/blood-2025-2197

Published: 2025

Journal Articles

Cardiac risk factors and cardiac events in patients with newly diagnosed amyloid light chain (AL) amyloidosis from the Phase 2 aquarius study of daratumumab (DARA) plus bortezomib, cyclophosphamide, and dexamethasone (D-VCd)

Vaishali Sanchorawala, Monique Minnema, Yvonne Efebera, Angela Dispenzieri, Ashutosh Wechalekar, Martha Grogan, Antoine Huart, Michael Rosenzweig, Brandon Blue, Faizi Jamal, Christopher Pericone, Sandra Vasey, Yuping Chen, Matteo Loi, NamPhuong Tran, Efstathios Kastritis

Blood (2025) 146 (Supplement 1): 691.

https://doi.org/10.1182/blood-2025-691

Published: 2025

Journal Articles

Prognostic impact of cytogenetic abnormalities detected by FISH in AL amyloidosis with daratumumab-based frontline therapy

Rajshekhar Chakraborty, Saurabh Zanwar, Ute Hegenbart, Divaya Bhutani, Morie A. Gertz, Angela Dispenzieri, Shaji Kumar, Anita D’Souza, Anannya Patwari, Andrew Cowan, GuiZhen Chen, Paolo Milani, Giovanni Palladini, Vaishali Sanchorawala, Geethika Bodanapu, Stefan O. Schönland, Suzanne Lentzsch, Eli Muchtar

Blood (2024) 144 (25): 2613–2624.

https://doi.org/10.1182/blood.2024025899

Published: 2024

Includes: Supplemental data

Journal Articles

Screening for AL Amyloidosis in Smoldering Multiple Myeloma

Blood (2024) 144 (Supplement 1): 6874.

https://doi.org/10.1182/blood-2024-201755

Published: 2024

Journal Articles

Isatuximab in Relapsed AL Amyloidosis: Results of a Prospective Phase II Trial (SWOG S1702)

Blood (2024) 144 (Supplement 1): 3378.

https://doi.org/10.1182/blood-2024-208341

Published: 2024

Journal Articles

A Medical Chart Review of Healthcare Costs in Patients with Systemic Amyloid Light Chain Amyloidosis By Mayo 2012 Stage in the United States

Morie A. Gertz, Heather J. Landau, Vaishali Sanchorawala, Manisha Bhutani, Jeffrey A. Zonder, Michael Rosenzweig, Gray Magee, Cynthia Campos, Irina Yermilov, Eunice Chang, Michael S. Broder, Preeti Bajaj

Blood (2024) 144 (Supplement 1): 3665.

https://doi.org/10.1182/blood-2024-206132

Published: 2024

Journal Articles

Model for Predicting Day-100 Stem Cell Transplant-Related Mortality in AL Amyloidosis

Blood (2024) 144 (Supplement 1): 4681.

https://doi.org/10.1182/blood-2024-206496

Published: 2024

Journal Articles

Epidemiological Characteristics and Clinical Outcomes of Patients with Monoclonal Gammopathy of Renal Significance (MGRS) Diagnosed in a Large Safety-Net Hospital in the US

Evgenia Granina, Joel Henderson, Kimberly A. Bertrand, Vaishali Sanchorawala, Raphael E. Szalat

Blood (2024) 144 (Supplement 1): 4680.

https://doi.org/10.1182/blood-2024-206486

Published: 2024

Journal Articles

Clinical Characteristics and Treatment Outcomes of Patients with AL Amyloidosis with Acquired Factor X Deficiency

Okan Cetin, Patric Teodorescu, Andrew Staron, Vaishali Sanchorawala, Raphael E. Szalat

Blood (2024) 144 (Supplement 1): 4671.

https://doi.org/10.1182/blood-2024-203221

Published: 2024

Journal Articles

A Phase III, Randomized Study of Daratumumab, Cyclophosphamide, Bortezomib and Dexamethasone (DARA-VCD) Induction Followed By Autologous Stem Cell Transplant or Dara-VCD Consolidation and Daratumumab Maintenance in Patients with Newly Diagnosed AL Amyloidosis

Patrick Hagen, Surbhi Sidana, Terri L. Parker, Brian A. Walker, Vaishali Sanchorawala, Jeffrey A. Zonder, Taxiarchis Kourelis, Anita D'Souza, Heather J. Landau, Adam Rosenthal, Antje Hoering, Sikander Ailawadhi, Robert Z. Orlowski

Blood (2024) 144 (Supplement 1): 3309.1.

https://doi.org/10.1182/blood-2024-208227

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Isatuximab for relapsed and/or refractory AL amyloidosis: results of a prospective phase 2 trial (SWOG S1702)

A phase I/II, open label, Study to evaluate safety, tolerability and efficacy of elranatamab in patients with relapsed or refractory AL amyloidosis: Interim report of phase I results

Effectiveness of second-line therapies following upfront daratumumab plus bortezomib, cyclophosphamide and dexamethasone: A new benchmark

Cyclin D1 immunostaining as a diagnostic surrogate for the t(11;14) translocation in AL amyloidosis

Single-cell transcriptomics of AL amyloidosis reveals pathogenic mechanisms, immune interactions and altered clonal and polyclonal plasma cell phenotypes

An open-label multicenter Phase 1/2 trial of venetoclax-dexamethasone in Relapsed/Refractory t(11;14)-positive systemic AL amyloidosis

IgD-related AL amyloidosis: Clinical features and outcomes

First 20-patient safety and efficacy data from nexicart-2, the first u.S. trial of CAR-T in R/R light chain (AL) amyloidosis, nxc-201

Sustained measurable residual disease (MRD) in light chain amyloidosis: The added value of durability over depth alone

Phase 1/2 dose escalation and expansion study of etentamig in patients with relapsed or refractory light chain amyloidosis

Impact-AL: A phase 2 clinical trial of teclistamab and daratumumab in previously untreated AL amyloidosis

Cardiac risk factors and cardiac events in patients with newly diagnosed amyloid light chain (AL) amyloidosis from the Phase 2 aquarius study of daratumumab (DARA) plus bortezomib, cyclophosphamide, and dexamethasone (D-VCd)

Prognostic impact of cytogenetic abnormalities detected by FISH in AL amyloidosis with daratumumab-based frontline therapy

Screening for AL Amyloidosis in Smoldering Multiple Myeloma

Isatuximab in Relapsed AL Amyloidosis: Results of a Prospective Phase II Trial (SWOG S1702)

A Medical Chart Review of Healthcare Costs in Patients with Systemic Amyloid Light Chain Amyloidosis By Mayo 2012 Stage in the United States

Model for Predicting Day-100 Stem Cell Transplant-Related Mortality in AL Amyloidosis

Epidemiological Characteristics and Clinical Outcomes of Patients with Monoclonal Gammopathy of Renal Significance (MGRS) Diagnosed in a Large Safety-Net Hospital in the US

Clinical Characteristics and Treatment Outcomes of Patients with AL Amyloidosis with Acquired Factor X Deficiency

A Phase III, Randomized Study of Daratumumab, Cyclophosphamide, Bortezomib and Dexamethasone (DARA-VCD) Induction Followed By Autologous Stem Cell Transplant or Dara-VCD Consolidation and Daratumumab Maintenance in Patients with Newly Diagnosed AL Amyloidosis

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only